CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: LINC00665 (ImmuneEditome ID:100506930)

1. Gene summary of enriched editing regions for LINC00665

check button Gene summary
Gene informationGene symbol

LINC00665

Gene ID

100506930

GeneSynonymsCIP2A-BP
GeneCytomap

19q13.12

GeneTypencRNA
GeneDescriptionCIP2A binding peptide
GeneModificationdate20230329
UniprotID.
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:36313461-36314501:-ENST00000585356.4ENSG00000232677.5LINC00665ncRNA_exonicL1M5,(A)n,AluSx1chr19:36313461-36314501:-.alignment
chr19:36313461-36314501:-ENST00000590657.1ENSG00000232677.5LINC00665ncRNA_exonicL1M5,(A)n,AluSx1chr19:36313461-36314501:-.alignment
chr19:36317144-36320766:-ENST00000438368.5ENSG00000232677.5LINC00665ncRNA_exonicAluJb,AluSx,AluJo,AluSz6,AluY,MER33,AluSx1chr19:36317144-36320766:-.alignment
chr19:36317144-36320766:-ENST00000590622.4ENSG00000232677.5LINC00665ncRNA_exonicAluJb,AluSx,AluJo,AluSz6,AluY,MER33,AluSx1chr19:36317144-36320766:-.alignment


Top

2. Tumor-specific enriched editing regions for LINC00665


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr19:36317144-36320766:-KIRPEER3.1729e-02image
ENSG00000232677.5,LINC00665KIRPEAG3.4529e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr19:36317144-36320766:-UCECEER2.8586e-021.8006e-022.0780e+01image
ENSG00000232677.5,LINC00665UCECEAG2.8586e-021.8006e-022.0780e+01image

Top

3. Enriched editing regions and immune related genes for LINC00665


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:36317144-36320766:-GBMEERENSG00000101019,UQCC1-0.42115.3116e-051.7400e-07-0.4061imageNADAR;FBL;NOP56;SRSF1;UPF1NAT_cells_gamma_deltaGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr19:36317144-36320766:-OVEERENSG00000143612,C1orf430.45551.3719e-111.1137e-120.4031imageNADAR;FBL;NOP56;SRSF1;UPF1NAMacrophages_M1GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr19:36317144-36320766:-OVEERENSG00000171155,C1GALT1C10.40632.0109e-091.3270e-120.4019imageNADAR;FBL;NOP56;SRSF1;UPF1NAMacrophages_M0GSVA_HALLMARK_PEROXISOME
chr19:36317144-36320766:-OVEERENSG00000077721,UBE2A0.40813.5884e-094.0653e-130.4102imageNADAR;FBL;NOP56;SRSF1;UPF1NAT_cells_CD8GSVA_HALLMARK_FATTY_ACID_METABOLISM
chr19:36317144-36320766:-THYMEERENSG00000269893,SNHG8-0.48751.2496e-044.4910e-05-0.4141imageNADAR;FBL;NOP56;SRSF1;UPF1NAT_cells_gamma_deltaGSVA_HALLMARK_PROTEIN_SECRETION
chr19:36317144-36320766:-THYMEERENSG00000202474,RNA5SP2830.35367.8713e-034.6182e-050.4135imageNNNAMonocytesGSVA_HALLMARK_MITOTIC_SPINDLE
chr19:36317144-36320766:-GBMEERENSG00000101019,UQCC1-0.42115.3116e-051.7400e-07-0.4061imageNADAR;FBL;NOP56;SRSF1;UPF1NAT_cells_gamma_deltaGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr19:36317144-36320766:-OVEERENSG00000143612,C1orf430.45551.3719e-111.1137e-120.4031imageNADAR;FBL;NOP56;SRSF1;UPF1NAMacrophages_M1GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr19:36317144-36320766:-OVEERENSG00000171155,C1GALT1C10.40632.0109e-091.3270e-120.4019imageNADAR;FBL;NOP56;SRSF1;UPF1NAMacrophages_M0GSVA_HALLMARK_PEROXISOME
chr19:36317144-36320766:-OVEERENSG00000077721,UBE2A0.40813.5884e-094.0653e-130.4102imageNADAR;FBL;NOP56;SRSF1;UPF1NAT_cells_CD8GSVA_HALLMARK_FATTY_ACID_METABOLISM
chr19:36317144-36320766:-THYMEERENSG00000269893,SNHG8-0.48751.2496e-044.4910e-05-0.4141imageNADAR;FBL;NOP56;SRSF1;UPF1NAT_cells_gamma_deltaGSVA_HALLMARK_PROTEIN_SECRETION
chr19:36317144-36320766:-THYMEERENSG00000202474,RNA5SP2830.35367.8713e-034.6182e-050.4135imageNNNAMonocytesGSVA_HALLMARK_MITOTIC_SPINDLE

More results



Top

4. Enriched editing regions and immune related splicing for LINC00665


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:36317144-36320766:-
GBMEERIRENSG00000101361.10chr202655933:2656034:2656400:2656549-0.39541.3649e-031.5056e-07-0.4080imageNADAR;FBL;NOP56;SRSF1;UPF1NAMonocytesGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000232677.5,LINC00665
GBMEAGIRENSG00000101361.10chr202655933:2656034:2656400:2656549-0.40571.0298e-037.9546e-08-0.4162imageNADAR;AIFM1;CELF2;CNBP;CSTF2T;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;EWSR1;FBL;FMR1;FTO;FUS;FXR2;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;LARP4B;LIN28A;LIN28B;MBNL2;MOV10;NOP56;NOP58;PTBP1;QKI;RBFOX2;RBM10;RBM22;RBM47;SAFB2;SRSF1;TAF15;TARDBP;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7BNAMonocytesGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000232677.5,LINC00665
GBMEAGIRENSG00000167110.12chr9128265787:128266325:128267193:128267259-0.32343.6101e-035.4234e-06-0.4002imageNADAR;AIFM1;CELF2;CNBP;CSTF2T;DGCR8;DHX9;EIF4A3;ELAVL1;EWSR1;FBL;FMR1;FUS;FXR2;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;LARP4B;LIN28A;LIN28B;MBNL2;MOV10;NOP56;NOP58;PTBP1;RBFOX2;RBM10;RBM22;RBM47;SAFB2;SRSF1;TAF15;TARDBP;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1NAMonocytesGSVA_HALLMARK_PEROXISOME
chr19:36317144-36320766:-
GBMEERMEXENSG00000122566.16chr726190124:26190460:26190992:26191011:26191055:26191128:26192494:26192577-0.37972.5481e-037.4895e-08-0.4170imageNADAR;FBL;NOP56;SRSF1;UPF1NAMonocytesGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000232677.5,LINC00665
GBMEAGMEXENSG00000122566.16chr726190124:26190460:26190992:26191011:26191055:26191128:26192494:26192577-0.37963.0291e-036.0560e-08-0.4196imageNADAR;AIFM1;CELF2;CNBP;CSTF2T;DGCR8;DHX9;DICER1;EIF4A1;EIF4A3;ELAVL1;EWSR1;FBL;FMR1;FTO;FUS;FXR2;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;LARP4B;LIN28A;LIN28B;MBNL2;MOV10;NOP56;NOP58;PTBP1;QKI;RBFOX2;RBM10;RBM22;RBM47;SAFB2;SRSF1;TAF15;TARDBP;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZFP36NAMonocytesGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr19:36317144-36320766:-
GBMEERIRENSG00000146830.9chr7100688203:100688718:100689301:100689448-0.31973.5202e-031.4946e-06-0.4229imageNADAR;FBL;NOP56;SRSF1;UPF1NAPlasma_cellsGSVA_HALLMARK_ADIPOGENESIS
ENSG00000232677.5,LINC00665
GBMEAGIRENSG00000146830.9chr7100688203:100688718:100689301:100689448-0.33481.9720e-038.2579e-07-0.4322imageNADAR;AIFM1;CELF2;CNBP;CSTF2T;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;FBL;FMR1;FTO;FUS;FXR2;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;LARP4B;LIN28B;MBNL2;MOV10;NOP56;NOP58;PTBP1;RBFOX2;RBM10;RBM22;SAFB2;SRSF1;TAF15;TARDBP;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7BNAPlasma_cellsGSVA_HALLMARK_ADIPOGENESIS
ENSG00000232677.5,LINC00665
OVEAGIRENSG00000059588.5chr1234405902:234406099:234410444:234410531-0.41303.5617e-091.6931e-12-0.4080imageNADAR;AIFM1;CELF2;CNBP;CSTF2T;DGCR8;DHX9;EIF4A3;ELAVL1;EWSR1;FBL;FMR1;FTO;FUS;FXR2;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;LARP4B;LIN28A;LIN28B;MBNL2;MOV10;NOP56;NOP58;PTBP1;QKI;RBFOX2;RBM10;RBM22;SAFB2;SRSF1;TAF15;TARDBP;U2AF2;UPF1;XRN2;YTHDC1;ZC3H7B;ZFP36TARBP1Macrophages_M1GSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000232677.5,LINC00665
OVEAGIRENSG00000162910.14chr1228107649:228107869:228108234:228108318-0.46312.0628e-111.3794e-13-0.4177imageNADAR;AIFM1;CNBP;CSTF2T;DGCR8;DICER1;EIF4A1;EIF4A3;ELAVL1;FBL;FMR1;FTO;FUS;FXR2;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;LARP4B;LIN28B;MOV10;NOP56;NOP58;PTBP1;RBFOX2;RBM10;RBM22;SAFB2;SRSF1;TAF15;TARDBP;U2AF2;UPF1;XRN2;YTHDF1NAMacrophages_M0GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
ENSG00000232677.5,LINC00665
OVEAGIRENSG00000205581.6chr2139345138:39345274:39347246:39347292-0.41823.5709e-092.0539e-13-0.4170imageNADAR;AIFM1;CELF2;CNBP;CSTF2T;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;EWSR1;FBL;FMR1;FTO;FUS;FXR2;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS2;LARP4B;LIN28A;LIN28B;MBNL2;MOV10;NOP56;NOP58;PTBP1;QKI;RBFOX2;RBM10;RBM22;RBM47;SAFB2;SRSF1;TAF15;TARDBP;U2AF2;UPF1;XRN2;YTHDC1;ZC3H7B;ZFP36NANK_cells_restingGSVA_HALLMARK_UV_RESPONSE_UP

More results



Top

5. Enriched editing regions and immune infiltration for LINC00665


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr19:36317144-36320766:-BRCAEERT_cells_regulatory_(Tregs)6.3527e-030.0873image
ENSG00000232677.5,LINC00665BRCAEAGT_cells_regulatory_(Tregs)8.0558e-030.0847image
chr19:36317144-36320766:-ESCAEERMast_cells_resting1.1087e-030.4210image
ENSG00000232677.5,LINC00665ESCAEAGMacrophages_M21.8774e-030.3998image
chr19:36317144-36320766:-GBMEERMonocytes6.5613e-030.2182image
ENSG00000232677.5,LINC00665GBMEAGMonocytes5.5607e-030.2224image
chr19:36317144-36320766:-HNSCEERT_cells_CD4_memory_resting4.8799e-02-0.2493image
ENSG00000232677.5,LINC00665HNSCEAGT_cells_CD4_memory_resting4.5026e-02-0.2535image
chr19:36317144-36320766:-KICHEERNK_cells_activated2.5581e-020.3527image
ENSG00000232677.5,LINC00665KICHEAGNK_cells_activated2.5581e-020.3527image
chr19:36317144-36320766:-KIRCEERDendritic_cells_resting5.3438e-030.1540image
ENSG00000232677.5,LINC00665KIRCEAGDendritic_cells_resting5.0230e-030.1550image
chr19:36317144-36320766:-KIRPEERMacrophages_M01.8553e-02-0.1643image
ENSG00000232677.5,LINC00665KIRPEAGMacrophages_M01.8289e-02-0.1647image
chr19:36317144-36320766:-LAMLEEREosinophils9.2052e-030.4224image
ENSG00000232677.5,LINC00665LAMLEAGEosinophils9.2052e-030.4224image
chr19:36317144-36320766:-LGGEERDendritic_cells_resting5.2295e-030.1385image
ENSG00000232677.5,LINC00665LGGEAGDendritic_cells_resting5.0501e-030.1389image
chr19:36317144-36320766:-LIHCEERT_cells_CD4_memory_resting2.3939e-02-0.2589image
ENSG00000232677.5,LINC00665LIHCEAGT_cells_CD4_memory_resting2.4634e-02-0.2577image
chr19:36317144-36320766:-LUADEERNK_cells_resting1.9344e-02-0.1487image
ENSG00000232677.5,LINC00665LUADEAGNK_cells_resting1.3986e-02-0.1562image
chr19:36317144-36320766:-LUSCEERB_cells_naive3.1417e-020.1465image
ENSG00000232677.5,LINC00665LUSCEAGB_cells_naive3.1323e-020.1466image
chr19:36317144-36320766:-MESOEERNK_cells_resting7.2681e-030.3613image
ENSG00000232677.5,LINC00665MESOEAGNK_cells_resting7.2734e-030.3613image
chr19:36313461-36314501:-OVEERT_cells_CD83.9447e-030.2456image
chr19:36317144-36320766:-OVEERT_cells_CD81.2824e-050.2540image
ENSG00000232677.5,LINC00665OVEAGT_cells_CD81.0119e-050.2569image
chr19:36317144-36320766:-PCPGEERDendritic_cells_resting1.6046e-020.1950image
ENSG00000232677.5,LINC00665PCPGEAGDendritic_cells_resting1.5515e-020.1954image
chr19:36317144-36320766:-PRADEERMacrophages_M01.4501e-02-0.1129image
ENSG00000232677.5,LINC00665PRADEAGMacrophages_M01.4696e-02-0.1127image
chr19:36317144-36320766:-SARCEERMast_cells_resting1.7919e-030.3800image
ENSG00000232677.5,LINC00665SARCEAGMast_cells_resting1.8016e-030.3799image
chr19:36317144-36320766:-SKCMEERT_cells_CD4_memory_resting5.6030e-04-0.2604image
ENSG00000232677.5,LINC00665SKCMEAGT_cells_CD4_memory_resting5.6030e-04-0.2604image
chr19:36317144-36320766:-THCAEERB_cells_memory1.1083e-02-0.1157image
ENSG00000232677.5,LINC00665THCAEAGB_cells_memory1.1980e-02-0.1145image
chr19:36317144-36320766:-THYMEERT_cells_CD4_memory_resting1.6029e-020.2518image
ENSG00000232677.5,LINC00665THYMEAGT_cells_CD4_memory_resting1.7952e-020.2476image
chr19:36317144-36320766:-UCSEERB_cells_memory5.1369e-030.4146image
ENSG00000232677.5,LINC00665UCSEAGB_cells_memory4.3102e-030.4222image
chr19:36317144-36320766:-UVMEERMonocytes4.0282e-020.3069image
ENSG00000232677.5,LINC00665UVMEAGMonocytes4.0282e-020.3069image


Top

6. Enriched editing regions and immune gene sets for LINC00665


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr19:36317144-36320766:-BLCAGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER2.0442e-040.2361image
ENSG00000232677.5,LINC00665BLCAGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG2.2536e-040.2345image
chr19:36317144-36320766:-BRCAGSVA_HALLMARK_APOPTOSISEER1.5553e-120.2237image
ENSG00000232677.5,LINC00665BRCAGSVA_HALLMARK_APOPTOSISEAG1.1460e-120.2249image
ENSG00000232677.5,LINC00665ESCAGSVA_HALLMARK_SPERMATOGENESISEAG3.6627e-03-0.3757image
chr19:36317144-36320766:-ESCAGSVA_HALLMARK_SPERMATOGENESISEER9.2037e-03-0.3421image
chr19:36317144-36320766:-GBMGSVA_HALLMARK_HEME_METABOLISMEER2.5538e-030.2415image
ENSG00000232677.5,LINC00665GBMGSVA_HALLMARK_HEME_METABOLISMEAG2.0983e-030.2460image
chr19:36317144-36320766:-HNSCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER3.5270e-020.2658image
ENSG00000232677.5,LINC00665HNSCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG3.6067e-020.2647image
ENSG00000232677.5,LINC00665KICHGSVA_HALLMARK_APICAL_SURFACEEAG4.0717e-02-0.3250image
chr19:36317144-36320766:-KICHGSVA_HALLMARK_APICAL_SURFACEEER4.0717e-02-0.3250image
ENSG00000232677.5,LINC00665KIRCGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG9.9599e-060.2420image
chr19:36317144-36320766:-KIRCGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER1.8804e-050.2346image
chr19:36317144-36320766:-KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEER8.7709e-04-0.2306image
ENSG00000232677.5,LINC00665KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.1007e-03-0.2264image
ENSG00000232677.5,LINC00665LAMLGSVA_HALLMARK_BILE_ACID_METABOLISMEAG3.8642e-020.3414image
chr19:36317144-36320766:-LAMLGSVA_HALLMARK_BILE_ACID_METABOLISMEER3.8642e-020.3414image
chr19:36317144-36320766:-LGGGSVA_HALLMARK_PEROXISOMEEER3.3496e-04-0.1774image
ENSG00000232677.5,LINC00665LGGGSVA_HALLMARK_PEROXISOMEEAG3.4661e-04-0.1767image
ENSG00000232677.5,LINC00665LIHCGSVA_HALLMARK_HEME_METABOLISMEAG1.5406e-040.4207image
chr19:36317144-36320766:-LIHCGSVA_HALLMARK_HEME_METABOLISMEER1.5827e-040.4201image
ENSG00000232677.5,LINC00665LUADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG4.0782e-030.1821image
chr19:36317144-36320766:-LUADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER5.7462e-030.1753image
chr19:36317144-36320766:-MESOGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.0863e-020.2941image
ENSG00000232677.5,LINC00665MESOGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.1899e-020.2924image
chr19:36313461-36314501:-OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER2.1154e-020.1975image
ENSG00000232677.5,LINC00665OVGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG3.4427e-140.4270image
chr19:36317144-36320766:-OVGSVA_HALLMARK_FATTY_ACID_METABOLISMEER2.5181e-140.4290image
chr19:36317144-36320766:-PCPGGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER2.8543e-030.2404image
ENSG00000232677.5,LINC00665PCPGGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG2.6441e-030.2414image
ENSG00000232677.5,LINC00665PRADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.9067e-030.1298image
chr19:36317144-36320766:-PRADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.9516e-030.1297image
ENSG00000232677.5,LINC00665SARCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.3667e-040.4557image
chr19:36317144-36320766:-SARCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.3715e-040.4556image
chr19:36317144-36320766:-SKCMGSVA_HALLMARK_MYC_TARGETS_V1EER5.5211e-04-0.2607image
ENSG00000232677.5,LINC00665SKCMGSVA_HALLMARK_MYC_TARGETS_V1EAG5.5211e-04-0.2607image
ENSG00000232677.5,LINC00665STADGSVA_HALLMARK_ADIPOGENESISEAG8.0231e-030.2172image
chr19:36317144-36320766:-STADGSVA_HALLMARK_ADIPOGENESISEER5.6079e-030.2274image
chr19:36317144-36320766:-TGCTGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.6934e-020.2506image
ENSG00000232677.5,LINC00665TGCTGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.6224e-020.2517image
chr19:36317144-36320766:-THCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER2.1415e-040.1680image
ENSG00000232677.5,LINC00665THCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG1.7551e-040.1703image
ENSG00000232677.5,LINC00665THYMGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.1375e-020.2410image
chr19:36317144-36320766:-THYMGSVA_HALLMARK_MITOTIC_SPINDLEEER2.4027e-020.2365image
chr19:36317144-36320766:-UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.2678e-020.2338image
ENSG00000232677.5,LINC00665UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.2901e-020.2333image
chr19:36317144-36320766:-UVMGSVA_HALLMARK_MYC_TARGETS_V1EER2.2490e-03-0.4440image
ENSG00000232677.5,LINC00665UVMGSVA_HALLMARK_MYC_TARGETS_V1EAG2.2490e-03-0.4440image


Top

7. Enriched editing regions and drugs for LINC00665


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr19:36317144-36320766:-BLCADMOGEER4.6546e-02-0.1278image
ENSG00000232677.5,LINC00665BRCAGNF.2EAG3.5463e-06-0.1477image
chr19:36317144-36320766:-BRCAGNF.2EER3.0815e-06-0.1487image
chr19:36317144-36320766:-CESCBexaroteneEER4.2289e-02-0.2158image
ENSG00000232677.5,LINC00665CESCBexaroteneEAG4.2289e-02-0.2158image
ENSG00000232677.5,LINC00665ESCALFM.A13EAG1.0791e-03-0.4185image
chr19:36317144-36320766:-ESCALFM.A13EER2.0273e-03-0.4004image
chr19:36317144-36320766:-GBMDMOGEER1.1927e-03-0.2588image
ENSG00000232677.5,LINC00665GBMDMOGEAG8.1000e-04-0.2672image
chr19:36317144-36320766:-HNSCAKT.inhibitor.VIIIEER3.4354e-020.2671image
ENSG00000232677.5,LINC00665HNSCAKT.inhibitor.VIIIEAG3.6146e-020.2646image
ENSG00000232677.5,LINC00665KICHBI.D1870EAG4.5765e-02-0.3177image
chr19:36317144-36320766:-KICHBI.D1870EER4.5765e-02-0.3177image
ENSG00000232677.5,LINC00665KIRCA.770041EAG5.0722e-04-0.1915image
chr19:36317144-36320766:-KIRCA.770041EER3.4940e-04-0.1968image
ENSG00000232677.5,LINC00665KIRPBleomycinEAG4.9686e-03-0.1955image
chr19:36317144-36320766:-KIRPABT.888EER4.6198e-03-0.1971image
chr19:36317144-36320766:-LGGCMKEER1.0534e-030.1622image
ENSG00000232677.5,LINC00665LGGCMKEAG1.0431e-030.1621image
chr19:36317144-36320766:-LIHCJNK.Inhibitor.VIIIEER4.7800e-03-0.3204image
ENSG00000232677.5,LINC00665LIHCJNK.Inhibitor.VIIIEAG4.8352e-03-0.3200image
chr19:36317144-36320766:-LUADCHIR.99021EER6.6175e-030.1724image
ENSG00000232677.5,LINC00665LUADCHIR.99021EAG9.7361e-030.1642image
chr19:36317144-36320766:-LUSCBMS.754807EER2.0622e-02-0.1574image
ENSG00000232677.5,LINC00665LUSCBMS.754807EAG2.0281e-02-0.1579image
chr19:36317144-36320766:-MESOCCT007093EER1.1109e-02-0.3430image
ENSG00000232677.5,LINC00665MESOCCT007093EAG1.1215e-02-0.3426image
chr19:36313461-36314501:-OVErlotinibEER6.7421e-03-0.2313image
chr19:36317144-36320766:-OVMG.132EER8.4210e-05-0.2300image
ENSG00000232677.5,LINC00665OVMG.132EAG1.0845e-04-0.2265image
ENSG00000232677.5,LINC00665PAADLapatinibEAG6.8559e-04-0.4599image
chr19:36317144-36320766:-PAADLapatinibEER6.8733e-04-0.4598image
chr19:36317144-36320766:-PCPGJNK.9LEER8.4724e-03-0.2128image
ENSG00000232677.5,LINC00665PCPGJNK.9LEAG8.6263e-03-0.2117image
chr19:36317144-36320766:-PRADAZD.0530EER6.0068e-04-0.1596image
ENSG00000232677.5,LINC00665PRADAZD.0530EAG5.0526e-04-0.1617image
ENSG00000232677.5,LINC00665SARCAP.24534EAG1.0415e-03-0.3975image
chr19:36317144-36320766:-SARCAP.24534EER1.0800e-03-0.3964image
chr19:36317144-36320766:-SKCMLFM.A13EER9.5363e-05-0.2931image
ENSG00000232677.5,LINC00665SKCMLFM.A13EAG9.5363e-05-0.2931image
ENSG00000232677.5,LINC00665STADDocetaxelEAG1.1089e-03-0.2655image
chr19:36317144-36320766:-STADLapatinibEER1.0780e-03-0.2697image
ENSG00000232677.5,LINC00665TGCTMetforminEAG2.7069e-02-0.2503image
chr19:36317144-36320766:-TGCTMetforminEER2.7527e-02-0.2496image
chr19:36317144-36320766:-THCAIPA.3EER1.8768e-030.1414image
ENSG00000232677.5,LINC00665THCAIPA.3EAG1.7146e-030.1426image
chr19:36317144-36320766:-THYMDasatinibEER7.4209e-040.3492image
ENSG00000232677.5,LINC00665THYMDasatinibEAG8.7207e-040.3449image
chr19:36317144-36320766:-UCECCHIR.99021EER2.5103e-030.2816image
ENSG00000232677.5,LINC00665UCECCHIR.99021EAG2.6055e-030.2806image
ENSG00000232677.5,LINC00665UCSMG.132EAG1.2689e-020.3728image
chr19:36317144-36320766:-UCSLenalidomideEER1.8229e-02-0.3545image
chr19:36317144-36320766:-UVMCCT018159EER4.6518e-030.4144image
ENSG00000232677.5,LINC00665UVMCCT018159EAG4.6518e-030.4144image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType